



Informational Webinar:

Collaborative Advancement of Cures for T1D

November 9, 2022

Joshua A. Vieth, PhD
Director, Research

Karen Ng
Senior Program Administrator

Introduction

Esther Latres, PhD

Vice President, Research

JDRF International

JDRF's Purpose

Our Vision:

A world without T1D

Our Mission:

Improving lives today and tomorrow by accelerating life-changing breakthroughs to cure, prevent and treat T1D and its complications.

JDRF Drives Research

JDRF has built a team of in-house researchers whose collective knowledge of the T1D field is unsurpassed

- Partner with leading T1D researchers, institutions, and experts around the world
- Bring other top researchers into the T1D field
- Direct and drive research across a strategic portfolio of work
- Continually seek out new opportunities and creative partnerships
- Support advances through grant funding, investments, and partnerships






JDRF has played a key role in every major T1D advance – drug, device, or cell research, made in the last 50 years.



JDRF Affects Every Step in the Pipeline

T1D Therapy Development

T1D Therapy Access



Discovery
Research

Translational
Research

Regulatory
Approval

Healthcare
Coverage

Clinical
Adoption

Better
Outcomes


- Fund Research
- Advocate for Government Funding of Research
- Invest Alongside For-Profit Funders in T1D Products
- Advance Clinical Trials

- Improve Prospects for Regulatory Approval


- Increase Coverage, Affordability, and Choice

- Support Continuing Healthcare Provider Education
- Education Community

Therapies for Every Stage of T1D



Current Funding Opportunity



Collaborative Advancement of Cures for T1D

- Bold advancement of therapies for all stages of disease requires significant resources as well as broad technological, subject-matter, and analytical expertise.
- Research plans to move us closer to safe, effective, therapies and cures for T1D likely need more expertise than is available in one laboratory or that can be funded by one grant award.
- Therefore, JDRF call for proposals that outline high-impact research by coordinated, multidisciplinary teams.
- Applicants to be considered are established or newly formed collaborative teams consisting of 2 or more laboratories with unique yet complementary expertise to address major gaps in the field.

Structure of the RFA

- Collaborative teams of 2-3 (or more) laboratories or research entities.
- Teams should identify a primary investigator and institution to serve as the lead applicant.
- Teams can be composed of collaborative groups of academic researchers, companies, or a combination of the two.

Budgeting Guidelines:

- Proposed budgets should be based upon up to three years of research.
- Partnerships containing two laboratories/partners may request up to \$500,000.00 per year (for a 3-year total of \$1.5M).
- Partnerships containing three or more laboratories/partners may request up to \$750,000.00 per year (for a 3-year total of \$2.25M).
- Funds may be distributed among partners as needed for the scope of the work, and do not have to be divided equally.



Applicant Eligibility

New or established teams of investigators with complementary expertise to facilitate bold advances toward a cure for T1D.

JDRF welcomes applications from all qualified individuals and encourages applications from members of groups underrepresented in the sciences.

Applicants must hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent and have a faculty position or equivalent at a college, university, medical school, or other research facility.

Domestic and foreign non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, industry, units of state and local governments, and eligible agencies of the federal government

No citizen requirements for this program.



Project Eligibility

Work proposed should address the development and enabling of clinical testing of therapies and approaches toward one or more of the following JDRF Cures Program goals:



Screening

- The development of data and analysis necessary for improving the prediction of high-risk individuals



Disease Modifying Therapies

- Accelerating the advancement of therapies that delay, stop, or reverse the development and progression of T1D, and enable pivotal clinical testing of these therapies.
- Developing immunotherapy approaches that stop the autoimmune attack, enhance immune regulation, or deviate inflammatory processes.
- Investigating approaches focused on promoting the function, survival, regeneration, and targeted delivery of therapies to beta cells.



Cell Therapy

- Accelerating the development and validation of strategies that ensure cell survival and function in alternative sites of implantation.
- Research that enables the development of safe, more efficacious, and longer-lasting cell therapies without the use of broad immunosuppression.

Project Eligibility


Teams that combine the expertise of established investigators in the field of T1D with those outside of the field that provide the required expertise to expand the scope and capabilities of the proposed research are of high priority.

Priority consideration will be given to proposals that outline courses of study that address multiple Cures Program Strategies (for example, investigation into beta cell transplantation and immunotherapy to promote transplanted cell survival).

Priority consideration will be given to projects that outline research plans that are approaching clinical translation. Consideration will be given to clinical trials (but applicants must reach out to the scientific contact prior to submitting an LOI).

Given the expanded nature of the resources available for projects selected for funding under this announcement, priority will be given to proposals that outline accelerated and bold courses of research to potentiate significant advances toward a cure for T1D

Examples of Possible Projects



Out of Scope

Projects that focus solely on advancing/developing methodology or streamlining processes

Studies focused solely on the development and/or broad phenotyping of animal models

**Studies that do not outline a clear transition from one development stage of research to the next
(Discovery / Preclinical / Clinical)**

Letter of Intent

Due December 8th, 2022

- Should be submitted online through the RMS360 portal
- 3 pages maximum for research outline
- Submission mechanism determined by collaborative group type:
 - Strategic Research Agreement (SRA)
 - For proposals with applicants/investigators at an academic institution or similar entity
 - Industry Development and Discovery Program (IDDP)
 - For proposals with applicants/investigators at an industry entity
 - JDRF strongly encourages collaborations between academic and industry institutions. Contact JDRF Staff if submitting a combined academic/industry proposal for guidance prior to preparing your LOI

Letters of Intent and Full Proposals (if invited) for this funding call must address the role and necessity of each individual investigator or research entity proposed as part of the collaborative team in the achievement of the research aims. If selected for a Full Proposal, a clear communication and coordination plan to facilitate the cooperative and multi-laboratory scope of the described research must be included. The distribution of budget across the institutions must be clearly described and justified.

Review Criteria

Significance

Relevance

Approach

Innovation

Environment


Appropriateness of Budget

Feasibility of Research Plan

**Strength/Suitability/Synergy of
Proposed Collaborative Team**

**Potential for Significant
Advancement of T1D Research**

Tips for Success



Collaborative Advancement of Cures for T1D

- 1) Familiarize yourself with the most recent T1D literature and the JDRF Research Strategy
- 2) No need to spend ½ page of 2-page LOI describing T1D, the prevalence of the disease, or the need for further developed therapies.
- 3) Familiarize yourself with the SRA/IDDP template and provide clear answers in each of the sections outlined.
- 4) Develop a collaborative team of researchers with complimentary areas of expertise that can each contribute to significant advancement of a focused research project.
- 5) Design your research plan to potentiate significant advancement toward enabling or conducting clinical testing
- 6) Don't hesitate to contact JDRF staff with any questions during the submission process.



THANK YOU!

Any Questions?

Joshua A. Vieth, PhD

Director, Research

jvieth@jdrf.org

Karen Ng

Senior Program Administrator

kng@jdrf.org

<https://grantcenter.jdrf.org>